MARKET

JAGX

JAGX

Jaguar Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2116
-0.0221
-9.46%
Closed 19:51 10/28 EDT
OPEN
0.2300
PREV CLOSE
0.2337
HIGH
0.2300
LOW
0.2049
VOLUME
5.33M
TURNOVER
--
52 WEEK HIGH
1.220
52 WEEK LOW
0.2049
MARKET CAP
11.92M
P/E (TTM)
-0.0574
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 27)
Benzinga · 21h ago
The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 26)
Benzinga · 1d ago
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 5d ago
Jaguar Health CEO And Lead Ethnobotanical Researcher Explain The Decades Of Research That Made It A Leader In Plant-Based Drug Treatment
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice.
Benzinga · 10/21 11:47
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2020 / Jaguar Health, Inc.
ACCESSWIRE · 10/16 20:15
Napo Pharmaceuticals, a Subsidiary of Jaguar Health, Launches Web-based NapoCares Platform to Enhance Patient Access to Mytesi
iAssist, a web-based component of the NapoCares™ patient support program, automates and streamlines the patient prescription processSAN FRANCISCO, CA / ACCESSWIRE / October 15, 2020 / Jaguar Health, Inc.
ACCESSWIRE · 10/15 12:30
Jaguar Health CEO Discusses Upcoming Virtual Event Highlighting Long-Term Treatment Needs Of Cancer Patients
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice.
Benzinga · 10/15 11:29
Jaguar Health and Its Subsidiary Bolster Management Team with Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs & Quality Assurance
Company Strengthens its Regulatory and Quality Capabilities to Support Mytesi® Commercial Markets as Well as Ongoing Clinical Studies Including the Pivotal Phase 3 Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted TherapySAN FRANCISCO, CA / ACCESSWIRE / October 14, 2020 / Jaguar Health, Inc.
ACCESSWIRE · 10/14 12:30
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAGX. Analyze the recent business situations of Jaguar Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JAGX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 405.57K
% Owned: 0.72%
Shares Outstanding: 56.33M
TypeInstitutionsShares
Increased
3
1.27K
New
8
177.99K
Decreased
1
46.36K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Independent Director
James Bochnowski
President/Chief Executive Officer/Director
Lisa Conte
Executive Vice President/Secretary
Steven King
Senior Vice President - Finance/Chief Accounting Officer
Carol Lizak
Chief Compliance Officer/General Counsel
Jonathan Wolin
Senior Vice President
Melissa Yeager
Independent Director
Gregory Divis
Independent Director
John Micek
Independent Director
Jiahao Qiu
Independent Director
Jonathan Siegel
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About JAGX
Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Jaguar Health Inc stock information, including NASDAQ:JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.